News

Press Releases

 
Press Releases
  Date Title and Summary View
May 19, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the Company will present in an oral session Phase 1b results of an ongoing clinical trial of CRLX101 in combination with weekly paclitaxel in...
May 18, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced a scheduled poster presentation on CRLX301 at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, at McCormick Pl...
May 10, 2016
Trial Conducted in Collaboration with the National Cancer Institute and AstraZeneca WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has bee...
May 2, 2016
Conference Call Today at 4:30 p.m. ET WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended March 31, 20...
Apr 25, 2016
Dr. Krasner to Present Phase 1b Results of CRLX101 in Combination with Weekly Paclitaxel in Relapsed Ovarian Cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Car...
Apr 25, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the first quarter 2016 on May 2. Management will conduct a conference call a...
Apr 19, 2016
Late-Breaker Presents Results from Investigator-Sponsored Trial of CRLX101 in Combination with Avastin® (bevacizumab) in Patients with Platinum-Resistant Ovarian Cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing ...
Apr 5, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President & Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York on...
Mar 23, 2016
Phase 1 Data Published in Proceedings of the National Academy of Sciences (PNAS) WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of clinical data f...
Mar 21, 2016
Maximum Tolerated Dose Identified for Once-Every-Three-Weeks Regimen WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the presentation of data from the Company's ongoing Pha...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Shareholder Tools